

Stephan Urban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7928296/publications.pdf>

Version: 2024-02-01

110
papers

9,877
citations

44069

48
h-index

36028

97
g-index

115
all docs

115
docs citations

115
times ranked

6589
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-clinical characterization of an HBsAg-specific monoclonal antibody preventing HBV spreading and reducing HBV, HDV and HBsAg in serum of humanized mice. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
2	Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. <i>Journal of Hepatology</i> , 2022, 77, 71-83.	3.7	31
3	Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. <i>Journal of Hepatology</i> , 2022, 77, 957-966.	3.7	34
4	New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. <i>Journal of Hepatology</i> , 2021, 74, 686-699.	3.7	37
5	De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA. <i>JHEP Reports</i> , 2021, 3, 100195.	4.9	33
6	A sensitive and Specific PCR-based Assay to Quantify Hepatitis B Virus Covalently Closed Circular (ccc) DNA While Preserving Cellular DNA. <i>Bio-protocol</i> , 2021, 11, e3986.	0.4	4
7	Virus-Derived Peptides for Hepatic Enzyme Delivery. <i>Molecular Pharmaceutics</i> , 2021, 18, 2004-2014.	4.6	1
8	Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. <i>Gut</i> , 2021, 70, 1782-1794.	12.1	125
9	Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates. <i>Journal of Hepatology</i> , 2021, 75, 311-323.	3.7	37
10	HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection. <i>Viruses</i> , 2021, 13, 1799.	3.3	17
11	Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence. <i>Viruses</i> , 2021, 13, 180.	3.3	34
12	Concentration of Na ⁺ -taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus. <i>Scientific Reports</i> , 2021, 11, 19799.	3.3	6
13	A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. <i>Viruses</i> , 2021, 13, 2371.	3.3	12
14	Interplay between Hepatitis D Virus and the Interferon Response. <i>Viruses</i> , 2020, 12, 1334.	3.3	23
15	Nuclear PYHIN proteins target the host transcription factor Sp1 thereby restricting HIV-1 in human macrophages and CD4 ⁺ T cells. <i>PLoS Pathogens</i> , 2020, 16, e1008752.	4.7	26
16	A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. <i>Antiviral Research</i> , 2020, 181, 104865.	4.1	17
17	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2020, 73, S52-S53.	3.7	54
18	Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. <i>Journal of Hepatology</i> , 2020, 73, S861-S862.	3.7	0

#	ARTICLE	IF	CITATIONS
19	Hepatitis B Virus DNA is a Substrate for the cGAS/STING Pathway but is not Sensed in Infected Hepatocytes. <i>Viruses</i> , 2020, 12, 592.	3.3	39
20	Stem cell-derived polarized hepatocytes. <i>Nature Communications</i> , 2020, 11, 1677.	12.8	60
21	Title is missing!. , 2020, 16, e1008752.		0
22	Title is missing!. , 2020, 16, e1008752.		0
23	Title is missing!. , 2020, 16, e1008752.		0
24	Title is missing!. , 2020, 16, e1008752.		0
25	Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus. <i>Scientific Reports</i> , 2019, 9, 10021.	3.3	23
26	SAT-202-Endogenous and exogenous IFN responses suppress HDV persistence during proliferation of hepatocytes in vitro. <i>Journal of Hepatology</i> , 2019, 70, e718-e719.	3.7	11
27	Towards curative therapy of chronic viral hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 61-73.	0.5	10
28	Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation. <i>Nature Communications</i> , 2019, 10, 2265.	12.8	39
29	The retinoic acid receptor (RAR) $\hat{\pm}$ -specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. <i>Antiviral Research</i> , 2019, 168, 146-155.	4.1	15
30	PS-053-A rapid point-of-care device for the diagnosis of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019, 70, e32-e33.	3.7	1
31	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2019, 70, e81.	3.7	93
32	PS-155-HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment. <i>Journal of Hepatology</i> , 2019, 70, e98.	3.7	4
33	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
34	Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. <i>Gut</i> , 2019, 68, 905-915.	12.1	122
35	Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	25
36	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. <i>Gut</i> , 2019, 68, 150-157.	12.1	65

#	ARTICLE	IF	CITATIONS
37	T cell receptor grafting allows virological control of hepatitis B virus infection. <i>Journal of Clinical Investigation</i> , 2019, 129, 2932-2945.	8.2	51
38	Quantification of Hepatitis B Virus Covalently Closed Circular DNA in Infected Cell Culture Models by Quantitative PCR. <i>Bio-protocol</i> , 2019, 9, e3202.	0.4	3
39	Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. <i>ELife</i> , 2019, 8, .	6.0	20
40	Drug-Drug Interaction Potential of the HBV and HDV Entry Inhibitor Myrcludex B Assessed <i>in vitro</i> . <i>Antiviral Therapy</i> , 2018, 23, 267-275.	1.0	12
41	Hepatitis D virus replication is sensed by MDA5 and induces IFN- λ responses in hepatocytes. <i>Journal of Hepatology</i> , 2018, 69, 25-35.	3.7	101
42	Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an <i>In Vitro</i> Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. <i>Journal of Virology</i> , 2018, 92, .	3.4	125
43	HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. <i>Gastroenterology</i> , 2018, 154, 1791-1804.e22.	1.3	128
44	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA <i>in vivo</i> . <i>Gut</i> , 2018, 67, 542-552.	12.1	125
45	Detection of Low Copy Number Integrated Viral DNA Formed by <i>In Vitro</i> Hepatitis B Infection. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	3
46	T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR. <i>Journal of Virology</i> , 2018, 92, .	3.4	35
47	Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. <i>Current Opinion in Virology</i> , 2018, 30, 68-79.	5.4	58
48	Editorial overview: Antiviral strategies: Virological and immunological basis for HBV cure. <i>Current Opinion in Virology</i> , 2018, 30, iv-vi.	5.4	6
49	Cellular Genomic Sites of Hepatitis B Virus DNA Integration. <i>Genes</i> , 2018, 9, 365.	2.4	53
50	Oral administration of a chimeric Hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice. <i>Vaccine</i> , 2018, 36, 5789-5795.	3.8	14
51	Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	6.5	22
52	Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes. <i>Hepatology</i> , 2017, 66, 703-716.	7.3	78
53	A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN- λ induction. <i>Journal of Hepatology</i> , 2017, 67, 669-679.	3.7	47
54	Stem cell-derived hepatocytes: A promising novel tool to study hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 66, 473-475.	3.7	9

#	ARTICLE	IF	CITATIONS
55	Hepatitis B Virus Infection of HepaRG Cells, HepaRG-hNTCP Cells, and Primary Human Hepatocytes. <i>Methods in Molecular Biology</i> , 2017, 1540, 15-25.	0.9	39
56	Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. <i>Scientific Reports</i> , 2017, 7, 15307.	3.3	72
57	HBV DNA Integration: Molecular Mechanisms and Clinical Implications. <i>Viruses</i> , 2017, 9, 75.	3.3	264
58	Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. <i>Viruses</i> , 2017, 9, 172.	3.3	30
59	Liver capsule: Entry and entry inhibition of hepatitis B virus and hepatitis delta virus into hepatocytes. <i>Hepatology</i> , 2016, 63, 633-633.	7.3	10
60	Restrictive influence of SAMHD1 on Hepatitis B Virus life cycle. <i>Scientific Reports</i> , 2016, 6, 26616.	3.3	56
61	Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. <i>Journal of Hepatology</i> , 2016, 64, S32-S40.	3.7	98
62	First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. <i>Journal of Hepatology</i> , 2016, 65, 483-489.	3.7	187
63	Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. <i>Journal of Hepatology</i> , 2016, 65, 490-498.	3.7	321
64	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. <i>EBioMedicine</i> , 2016, 11, 58-67.	6.1	45
65	Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 580-589.	17.8	129
66	Visualization of hepatitis B virus entry – novel tools and approaches to directly follow virus entry into hepatocytes. <i>FEBS Letters</i> , 2016, 590, 1915-1926.	2.8	12
67	A Slow Maturation Process Renders Hepatitis B Virus Infectious. <i>Cell Host and Microbe</i> , 2016, 20, 25-35.	11.0	50
68	Hepatitis B Virus Infection of a Mouse Hepatic Cell Line Reconstituted with Human Sodium Taurocholate Cotransporting Polypeptide. <i>Journal of Virology</i> , 2016, 90, 4827-4831.	3.4	35
69	Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. <i>Journal of Hepatology</i> , 2016, 64, 556-564.	3.7	63
70	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	7.3	269
71	Impaired uptake of conjugated bile acids and hepatitis b virus pres1 binding in na+taurocholate cotransporting polypeptide knockout mice. <i>Hepatology</i> , 2015, 62, 207-219.	7.3	116
72	Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+taurocholate cotransporting polypeptide inhibitor. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6815-6825.	3.7	35

#	ARTICLE	IF	CITATIONS
73	Hepatitis B Virus-Infected HepG2 ^h NTCP ⁺ Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8 ⁺ T Cells <i>In Vitro</i> . <i>Journal of Virology</i> , 2015, 89, 7433-7438.	3.4	26
74	NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry. <i>International Journal of Molecular Sciences</i> , 2014, 15, 2892-2905.	4.1	123
75	Inhibitors of Hepatitis B Virus Attachment and Entry. <i>Intervirolgy</i> , 2014, 57, 151-157.	2.8	60
76	Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. <i>Hepatology</i> , 2014, 60, 1483-1493.	7.3	120
77	Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes. <i>Gastroenterology</i> , 2014, 146, 1070-1083.e6.	1.3	627
78	Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes. <i>Gastroenterology</i> , 2014, 147, 48-64.	1.3	293
79	Entry of hepatitis B and C viruses – recent progress and future impact. <i>Current Opinion in Virology</i> , 2014, 4, 58-65.	5.4	43
80	Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. <i>Journal of Hepatology</i> , 2014, 60, 723-731.	3.7	217
81	The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. <i>Journal of Hepatology</i> , 2013, 58, 861-867.	3.7	286
82	Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. <i>Hepatology</i> , 2013, 58, 31-42.	7.3	113
83	Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. <i>Hepatology</i> , 2013, 58, 43-53.	7.3	102
84	Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer. <i>Molecular Pharmaceutics</i> , 2013, 10, 2230-2236.	4.6	6
85	Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors. <i>PLoS ONE</i> , 2013, 8, e58340.	2.5	61
86	Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. <i>Hepatology</i> , 2012, 55, 373-383.	7.3	108
87	Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. <i>Hepatology</i> , 2012, 55, 685-694.	7.3	190
88	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. <i>PLoS ONE</i> , 2011, 6, e24142.	2.5	9
89	Solid-Phase Synthesis of the Lipopeptide Myr-HBVpreS/2-78, a Hepatitis B Virus Entry Inhibitor. <i>Molecules</i> , 2010, 15, 4773-4783.	3.8	19
90	Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction. <i>Journal of Virology</i> , 2010, 84, 1989-2000.	3.4	201

#	ARTICLE	IF	CITATIONS
91	The Pre-S2 Domain of the Hepatitis B Virus Is Dispensable for Infectivity but Serves a Spacer Function for L-Protein-Connected Virus Assembly. <i>Journal of Virology</i> , 2010, 84, 3879-3888.	3.4	78
92	The replication cycle of hepatitis B virus. <i>Journal of Hepatology</i> , 2010, 52, 282-284.	3.7	96
93	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. <i>Nature Biotechnology</i> , 2008, 26, 335-341.	17.5	369
94	Primary Human Hepatocytes Are Susceptible to Infection by Hepatitis Delta Virus Assembled with Envelope Proteins of Woodchuck Hepatitis Virus. <i>Journal of Virology</i> , 2008, 82, 7276-7283.	3.4	28
95	An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus. <i>BMB Reports</i> , 2008, 41, 640-644.	2.4	19
96	Viral and cellular determinants involved in hepadnaviral entry. <i>World Journal of Gastroenterology</i> , 2007, 13, 22.	3.3	245
97	Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. <i>Hepatology</i> , 2007, 46, 1759-1768.	7.3	366
98	Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. <i>EMBO Journal</i> , 2007, 26, 4160-4167.	7.8	95
99	Characterization of a hepatitis B and hepatitis delta virus receptor binding site. <i>Hepatology</i> , 2006, 43, 750-760.	7.3	145
100	Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein. <i>Journal of Virology</i> , 2005, 79, 1613-1622.	3.4	312
101	Mapping of the Hepatitis B Virus Attachment Site by Use of Infection-Inhibiting preS1 Lipopeptides and Tupaia Hepatocytes. <i>Gastroenterology</i> , 2005, 129, 234-245.	1.3	225
102	Nonlinear partial differential equations and applications: Infection of a human hepatoma cell line by hepatitis B virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 15655-15660.	7.1	1,075
103	Inhibition of Duck Hepatitis B Virus Infection by a Myristoylated Pre-S Peptide of the Large Viral Surface Protein. <i>Journal of Virology</i> , 2002, 76, 1986-1990.	3.4	47
104	Envelope Protein-Mediated Down-Regulation of Hepatitis B Virus Receptor in Infected Hepatocytes. <i>Journal of Virology</i> , 2001, 75, 143-150.	3.4	39
105	A Soluble Form of the Avian Hepatitis B Virus Receptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 5707-5715.	3.4	21
106	Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. <i>Oncogene</i> , 1998, 16, 2051-2063.	5.9	105
107	Avian Hepatitis B Virus Infection Is Initiated by the Interaction of a Distinct Pre-S Subdomain with the Cellular Receptor gp180. <i>Journal of Virology</i> , 1998, 72, 8089-8097.	3.4	69
108	Carboxypeptidase D (gp180), a Golgi-Resident Protein, Functions in the Attachment and Entry of Avian Hepatitis B Viruses. <i>Journal of Virology</i> , 1998, 72, 8098-8104.	3.4	96

#	ARTICLE	IF	CITATIONS
109	The role of hepatitis B virus (HBV) in the development of hepatocellular carcinoma. Seminars in Virology, 1996, 7, 333-347.	3.9	23
110	Interconvertible of a vitamin B6 coenzyme analog derived from pyridoxal 5â€²-phosphate and rhodanine. Tetrahedron, 1996, 52, 14787-14800.	1.9	6